Endothelin antagonism: stepping into the spotlight
- PMID: 37931628
- DOI: 10.1016/S0140-6736(23)02419-4
Endothelin antagonism: stepping into the spotlight
Conflict of interest statement
ND has consulted for Travere Therapeutics on sparsentan in patients with IgA nephropathy, participated in an advisory board for Travere Therapeutics on current unmet need in patients with chronic kidney disease, and received research funding for an investigator-initiated study to investigate the benefits of sparsentan (a dual endothelin-renin angiotensin system blocker) in patients with antineutrophil cytoplasm antibody-associated vasculitis from Travere Therapeutics. GBC declares no competing interests.
Comment on
-
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.Lancet. 2023 Nov 25;402(10416):2004-2017. doi: 10.1016/S0140-6736(23)02230-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931629 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources